2023
Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Alvarez E, Longbrake E, Rammohan K, Stankiewicz J, Hersh C. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Multiple Sclerosis And Related Disorders 2023, 79: 105009. PMID: 37783194, DOI: 10.1016/j.msard.2023.105009.Peer-Reviewed Original ResearchConceptsRisk of infectionCD20 therapySecondary hypogammaglobulinemiaMultiple sclerosisAnti-CD20 therapySerum immunoglobulin levelsB cell levelsDisease managementImmunoglobulin levelsSerious infectionsTherapy clinical trialsPotential complicationsClinical trialsHypogammaglobulinemiaPatientsTreatment approachesTherapyInfectionSclerosisRiskPossible mechanismMedicationsBest practice approachComplicationsPathogenesis
2021
Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
Levin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, Masown K, Rimmer KT, Diaconu CI, Onomichi KB, Leavitt VM, Levine LL, Strauss‐Farber R, Vargas WS, Banwell B, Bar‐Or A, Berger JR, Goodman AD, Longbrake EE, Oh J, Weinstock‐Guttman B, Thakur KT, Edwards KR, Riley CS, Xia Z, De Jager PL, Collaborative M. Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases. Annals Of Clinical And Translational Neurology 2021, 8: 918-928. PMID: 33616290, PMCID: PMC8013889, DOI: 10.1002/acn3.51314.Peer-Reviewed Original ResearchConceptsNeuroinflammatory disordersMultiple sclerosisCOVID-19Year-long prospective studyPotential risk factorsPatient reported experienceTesting shortagesNeurological disabilityLiver diseaseNeuroinflammatory diseasesTelemedicine visitsProspective studyPotential confoundersMS casesRisk factorsNeurological careSevere casesTreatment changesSymptom criteriaEarly changesMore depressionReference groupCase prevalenceDisease managementGreater likelihood